2. Signaling Pathways
  3. Vitamin D Related/Nuclear Receptor
  4. Estrogen Receptor/ERR
  5. Estrogen receptor Isoform
  6. Estrogen receptor Antagonist

Estrogen receptor Antagonist

Estrogen receptor Antagonists (5):

Cat. No. Product Name Effect Purity
  • HY-109176
    Giredestrant
    		Antagonist 99.52%
    Giredestrant (GDC-9545), a non-steroidal estrogen receptor (ER) ligand, is an orally active and selective ER antagonist. Giredestrant potently competes with Estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity.
  • HY-148789
    Palazestrant
    		Antagonist 98.96%
    Palazestrant is an antiestrogen and antineoplastic agent. Palazestrant can completely inhibit the activity of 17b-estradiol (E2) with IC50 value of 6.4 nM, and inhibit the proliferation of MCF7 and CAMA-1 cells with IC50 value of 1.4-1.6 nM. Palazestrant can inhibit ER+/HER2+ cancer.
  • HY-135903
    Giredestrant tartrate
    		Antagonist
    Giredestrant tartrate (GDC-9545 tartrate), a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist. Giredestrant tartrate potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Anti-tumor activity.
  • HY-143267
    Estrogen receptor antagonist 8
    		Antagonist
    Estrogen receptor antagonist 8 is a potent ER-antagonist with in vivo anti-uterotrophic potential (EC50 = 4.160 μM).
  • HY-143439
    LX-039
    		Antagonist
    LX-039 is a highly potent, selective and orally active estrogen receptor degrader with EC50 value of 2.29 nM. LX-039 has indole C-3 chlorine atom. LX-039 exhibits excellent mouse pharmacokinetics, low clearance, high Cmax and oral exposure. LX-039 has anti-tumor activity.